Paris, Ile-de-France, France In 2004 was created Credit Agricole CIB, which is appeared as Corporate Investor. The company was established in Europe in France. The main department of described Corporate Investor is located in the Paris.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Credit Agricole CIB, startups are often financed by West Deutsche Landesbank Girozentrale, Technomark Medical Ventures, Temasek Holdings. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Gimv, Forbion Capital Partners. In the next rounds fund is usually obtained by Omnes Capital, Ventech, Forbion Capital Partners.
We can highlight the next thriving fund investment areas, such as Pharmaceutical, Business Intelligence. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight BioVex, Themis Bioscience, SETL.
Speaking about the real fund results, this Corporate Investor is 2 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Credit Agricole CIB works on 27 percentage points more the average amount of lead investments. The increased amount of exits for fund were in 2014. The usual things for fund are deals in the range of more than 100 millions dollars. The fund is generally included in less than 2 deals every year. The high activity for fund was in 2007.
Related Funds
| Fund Name | Location |
| Angeles Investment Advisors, LLC | - |
| Bankia | Community of Madrid, Madrid, Spain |
| China Oceanwide USA | California, San Francisco, United States |
| Elite Learning | Beijing, China, Haidian |
| Gainesborough Investments | Lexington, Massachusetts, United States |
| KD Partners | - |
| Lorax Capital Partners | Egypt, Texas, United States |
| Natural Resources Canada | Canada, Ontario, Ottawa |
| NextGen Venture Partners | Baltimore, Maryland, United States |
| OZF Investments | Delaware, United States, Wilmington |
| Paragon Capital | New York, New York, United States |
| Rivet Ventures | California, San Francisco, United States |
| Ruer Touzi | China, Hubei, Wuhan |
| Salus Partners SA | Lausanne, Switzerland, Vaud |
| Seaya Ventures | Madrid, Madrid, Spain |
| Toray Engineering | Hokkaido Prefecture, Japan, Sapporo |
| Transinfo Group | Beijing, Beijing, China |
| Venture Builders | Incline Village, Nevada, United States |
| WEFA GmbH | Germany, Thuringen, Thuringia |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cleyrop | $11M | 02 Jun 2023 | Paris, Ile-de-France, France | ||
AugmentedCISO | $2M | 09 Mar 2022 | Lyon, Rhone-Alpes, France | ||
Cobase | $11M | 10 Jun 2020 | North Holland | ||
Themis Bioscience | $5M | 23 May 2011 | Vienna, Austria | ||
Fovea Pharmaceuticals | $30M | 18 Dec 2007 | Paris, Ile-de-France, France | ||
CircuLite | $5M | 23 Apr 2007 | Framingham, Massachusetts, United States | ||
Fovea Pharmaceuticals | $24M | 07 Nov 2005 | Ile-de-France |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cleyrop | $11M | 02 Jun 2023 | Paris, Ile-de-France, France | ||
AugmentedCISO | $2M | 09 Mar 2022 | Lyon, Rhone-Alpes, France | ||
Cobase | $11M | 10 Jun 2020 | North Holland | ||
Themis Bioscience | $5M | 23 May 2011 | Vienna, Austria | ||
Fovea Pharmaceuticals | $30M | 18 Dec 2007 | Paris, Ile-de-France, France | ||
CircuLite | $5M | 23 Apr 2007 | Framingham, Massachusetts, United States | ||
Fovea Pharmaceuticals | $24M | 07 Nov 2005 | Ile-de-France |
